Maze Therapeutics (MAZE) Operating Expenses (2024 - 2026)

Maze Therapeutics has reported Operating Expenses for 3 years, with the latest figure at $46.6 million in Q1 2026.

• Quarterly Operating Expenses rose 31.5% year-over-year to $46.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $154.1 million (up 31.33% YoY) and the FY2025 annual result came in at $142.9 million, up 30.01% from the prior year.
• Operating Expenses climbed to $46.6 million in Q1 2026 per MAZE's latest filing, from $38.1 million in the prior quarter.
• Over five years, Operating Expenses peaked at $46.6 million in Q1 2026 and troughed at $25.4 million in Q2 2024.
• A 3-year average of $33.3 million and a median of $33.0 million in 2025 frame the typical range for Operating Expenses.
• The widest YoY moves for Operating Expenses: up 43.34% in 2025, down 23.33% in 2025.
• Over 3 years, Operating Expenses stood at $29.7 million in 2024, then rose by 28.03% to $38.1 million in 2025, then increased by 22.32% to $46.6 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $46.6 million, $38.1 million, and $33.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.